The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUV$_{\text{max}}$ on Predicting Survival in Patients with Rectal Cancer

Abstract

Objectives: The aim of this study was to evaluate the impact of maximum standard uptake value (SUV$_{\text{max}}$) of the primary tumor and locoregional metastatic lymph node in predicting survival in patients with the preoperative rectal adenocarcinoma.

Methods: One hundred and fifteen patients [mean age ± standard deviation (SD): 58.7±11.4 years] with biopsy-proven rectal adenocarcinoma underwent $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging for the staging were included in this study. All patients were followed-up for a minimum of 12 months (mean ± SD: 29.7±13.5 months). Tumor-node-metastasis 2017 clinical staging, SUV$_{\text{max}}$ of the primary rectal tumor and locoregional lymph nodes on the PET/CT studies were evaluated.

Results: All patients had increased FDG activity of the primary tumor. The mean ± SD SUV$_{\text{max}}$ of the primary tumor and locoregional metastatic lymph node were 21.0±9.1 and 4.6±2.8, respectively. Primary tumor SUV$_{\text{max}}$ did not have an effect on predicting survival (p=0.525) however locoregional metastatic lymph node SUV$_{\text{max}}$ had an effect (p<0.05) on predicting survival. Clinical stage of the disease was a factor predicting survival (p<0.001).

Conclusion: $^{18}$F-FDG PET/CT is an effective imaging modality for detecting primary tumors and metastases in rectal adenocarcinoma and clinical stage assessment with PET/CT had an effect on predicting survival. Furthermore, in our study locoregional lymph node SUV$_{\text{max}}$ was defined as a factor in predicting survival.

Keywords: Rectal adenocarcinoma, $^{18}$F-FDG PET/CT, staging, SUV$_{\text{max}}$, prognosis

Öz

Amaç: Çalışmamızın amacı preoperatif rektum adenokanserli olan hastalarda sağkalımı öngörmede primer tümör ve lokorejyonel metastatik lenf nodu maksimum standart alım değeri (SUV$_{\text{max}}$) değerinin etkinliğini değerlendirmektir.

Yöntem: Bu çalışmaya, biyopsi ile kanıtlanmış rektal adenokarsinoma ile evreleme amaçlı $^{18}$F-florodeoksiglikoz (FDG) pozitron emisyon tomografisi/bilgisayarlı tomografisi (PET/BT) görüntüleme yapılan 115 hasta [ortalama yaş ± standart sapma (SS): 58,7±11,4 yıl] dahil edildi. Tüm hastaların en az 12 ay (ortalama ± SS: 29.7±13.5 ay) takip edildi. Tümör-nodül-metastaz 2017 klinik evreleme, primer rektal tümör SUV$_{\text{max}}$ ve lokorejyonel lenf nodu SUV$_{\text{max}}$ değerlerini değerlendirildi.

Bulgular: Tüm hastalarda primer tümörde artmış FDG tutulumu saptandı. Primer tümör ve lokorejyonel metastatik lenf nodu ortalaması SUV$_{\text{max}}$ "lan srasıyla 21,0±9,1 ve 4,6±2,8 idi. Primer tümör SUV$_{\text{max}}$'ın sağkalımı öngörmede bir etkisi saptanmamış (p>0,525) lokal metastatik lenf nodu SUV$_{\text{max}}$'ın sağkalımı öngörmede etkisi saptandı (p<0,05). Hastaların klinik evresi sağkalımı öngören bir faktördü (p<0,001).

Sonuç: $^{18}$F-FDG PET/BT rektum kanserinde primer tümör ve metastazlarının saptanmasıda etkili bir görüntüleme yöntemi olup lokorejyonel lenf nodu SUV$_{\text{max}}$ değerlerinin prognostik değerinin bulunduğu ve rektum kanserinin tedavi öncesi preoperatif evrelemede hastaların tedavi yönetimine önemli katkılar sağlayacağı düşünülmüştür.

Anahtar kelimeler: Rektum kanseri, $^{18}$F-FDG PET/BT, evreleme, SUV$_{\text{max}}$, prognoz

Address for Correspondence: Göksel Alçın MD, University of Health and Sciences, Istanbul Training and Research Hospital, Clinic of Nuclear Medicine, Istanbul, Turkey Phone: +90 553 979 33 83 E-mail: gokselalcin@hotmail.com.tr ORCID ID: orcid.org/0000-0003-2268-9606 Received: 28.10.2019 Accepted: 07.01.2020

©Copyright 2020 by Turkish Society of Nuclear Medicine
Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.
Introduction

Colorectal cancer is the third most common cancer in men and the second most common in women (1). Furthermore, it is one of the most important causes of cancer-related morbidity and mortality, globally (2). The primary treatment is surgical resection of the primary tumor and coupled with a (neo) adjuvant therapy increases the rates of survival of colorectal carcinoma (3). The importance of clinical staging with positron emission tomography/computed tomography (PET/CT) is established (4), the effect of the maximum standard uptake value (SUV$_{\text{max}}$) acquired with $^{18}$F-fluorodeoxyglucose (FDG) PET/CT on survival in initial staging has been evaluated by several studies. Primary tumor SUV$_{\text{max}}$ is related to survival in some studies (5,6) however, some authors reported that primary tumor SUV$_{\text{max}}$ was not associated with survival (7). On the other hand, the effect of metastatic locoregional lymph node FDG uptake level on survival has not been sufficiently studied. The aim of this study was to analyze the effect of the primary tumor and locoregional metastatic lymph node SUV$_{\text{max}}$ and stage of disease detected with $^{18}$F-FDG PET/CT on the survival of patients with rectal adenocarcinoma.

Materials and Methods

The study was approved by the Local Ethics Committee of Istanbul University Istanbul Medical Faculty of (2015/1867). The patients with histologically proven rectal adenocarcinoma who underwent FDG-PET/CT staging were assessed retrospectively. Clinical follow-up was performed until September 2015.

Localization of tumor was categorized as upper, mid rectal and distal rectal. Clinical staging was achieved using tumor-node-metastasis (TNM) staging provided by the American Joint Committee on Cancer Colon and Rectum Cancer Staging 8th Edition after assessing pathology reports, CT and PET/CT images.

PET/CT Protocol

Patient Preparation

Patients with blood glucose levels lower than 200 mg/dL after at least 6 h of fasting were admitted for the procedure. Patients received an intravenous injection of 5.4 MBq/kg $^{18}$F-FDG and then rested for approximately 60 min before undergoing imaging. Patients were instructed to discontinue oral antidiabetic ‘metformin’ use 3 days before PET/CT imaging. Long-acting insulin treatment was allowed 12 hours before $^{18}$F-FDG injection. Patients were administered oral contrast media 12 hours before imaging. All of the patients were instructed to refrain any muscular activity to avoid muscle uptake during the distribution phase of injected $^{18}$F-FDG.

PET/CT Imaging

PET/CT scan was performed using a Biograph 6 True Point HD LSO (Siemens Healthcare, Molecular Imaging, Knoxville, Tennessee, USA) integrated device. Initially, a CT scan (130-136 keV; 60-90 mAs) from vertex to upper thighs was performed in a single step which was used for attenuation correction of PET/CT images. The PET images were iteratively reconstructed with 5 mm thickness (TrueX option, subsets=21, iterations=3). A PET emission scan was acquired using whole-body mode following the CT scan. Six to 9 bed positions were used with an acquisition time of 3 minutes for each bed position. Additional imaging of the lower extremities was carried out in patients with multiple metastases. The PET data were reconstructed using 3D PET reconstruction with a system matrix derived from point source measurements.

Image Analysis

All images were examined on an LCD monitor as attenuation-corrected and uncorrected multiplanar PET, CT and PET/CT fusion cross-sections (maximum intensity projection) using the eSOFT software. $^{18}$F-FDG-PET/CT studies were reviewed for abnormally increased tracer uptake foci by a nuclear medicine physician with minimum 5 years of experience. Each focal uptake identified in PET images was correlated in the corresponding CT sections and a PET/CT scan was considered to be positive if one or more areas of abnormal $^{18}$F-FDG uptake were noted with a corresponding abnormality in CT. Furthermore, focally increased $^{18}$F-FDG accumulations of lymph nodes higher than the background activity, a short axis of 6 mm or larger, round shaped and fatty hilum loss were considered as pathological lymph nodes. Pathological FDG uptake in the liver was assumed as metastasis. The quantification was made by calculating the SUV that was used as a relative measure of $^{18}$F-FDG uptake. The simple expression for SUV was the ratio of tracer activity concentration (C) in the region of interest and the decay-corrected amount of injected activity (kBq) per weight of the patient (gr): SUV=C (kBq/mL)/[injection activity (kBq)/patient’s weight (g)].

Histopathological Analysis

All patients had primary tumor resection and lymph node dissection. Besides primary tumor and lymph nodes pathology, largest tumor diameter, venous invasion, angiolymphatic invasion, perineural invasion, surgical margins, and K-ras mutation status were evaluated in the pathology department.
Statistical Analysis

The normality of the data distribution was assessed with the Shapiro-Wilk test. Non-parametric data were presented as median and minimum-maximum ranges, while parametric data as means ± standard deviation (SD). Nominal and categorical variables were presented as frequencies and percentages. The parametric distribution was compared with the Student t-test in independent groups, and with the Mann-Whitney U test in the rest. Survival was evaluated by the Kaplan-Meier method. Categorical variables were evaluated with chi-square and Fisher’s Exact Contingency tests. The tests were two-sided. p<0.05 was accepted as significant. Statistical analysis was performed with SPSS statistical software, version 21.0 (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). The receiver operating characteristics (ROC) was applied to determine the threshold value for the optimal inventory SUV\textsubscript{max}. Sensitivity, specificity, positive-negative predictive values and accuracy rates were calculated for different threshold values.

Results

We reviewed data of 115 patients that underwent 18F-FDG PET/CT for initial staging. Thirty nine (34%) patients were female and 76 (66%) patients were male. The mean ± SD of patients was 58.7±11.4 (range=31-82 y). All patients underwent surgery and their histopathologic diagnosis was rectal adenocarcinoma. According to TNM, 66 patients had pN stage 0, 37 had pN stage 1 and 20 had pN stage 2 disease. Eleven patients had stage 1, 42 had stage 2, 39 had stage 3 disease and 23 had metastatic disease in initial staging (Table 1) (8). Subsequent to initial 18F-FDG PET/CT scan, all patients were followed-up for a 12-75 (29.7) months period and the estimated 5-year survival was found to be 61.8 ±2.9 months (Figure 1). Increased pathological 18F-FDG uptake in primary tumor was observed on PET/CT in all patients. The mean ± SD SUV\textsubscript{max} of the primary tumor was 21.0±9.1 (7.6-55). There was no significant relation between primary tumor SUV\textsubscript{max} and disease-free survival (DFS) or overall survival (OS) (p=0.760 and p=0.525) (Table 2).

Fifty eight out of 115 patients (50.4%) had locoregional lymph node with increased 18F-FDG uptake in initial PET/CT. Histologically proven metastatic LNs were found in 39 out of 115 patients (33.9%). Thirty of the PET/CT findings were true positive, 28 false positive, 48 true negative and 9 false negative. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET/CT were 76.9%, 63.1%, 51.7%, 84.2% and 67.8%, respectively.

The mean ± SD SUV\textsubscript{max} of metastatic lymph nodes were 4.6±2.8 (1.7-14.9). There was a significant correlation between locoregional metastatic lymph node SUV\textsubscript{max} and DFS or OS (p=0.049 and p=0.045, respectively). Also in accordance with the ROC curve (Figure 2) when the cut-off point for the lymph node SUV\textsubscript{max} was taken as 3.55; the sensitivity and specificity were 66.7% and 54.5% for DFS, 72.7% and 54.2% for OS, respectively. Metastatic lymph node SUV\textsubscript{max} was higher in the patient group who died compared with the individuals who survived [5.8 (2.5-14.9) vs 3.5 (1.7-12.0)].

The lymph node SUV\textsubscript{max} was higher in the patients as the stage of the disease increased and it was found to be statistically significant (p=0.002). The mean ± SD SUV\textsubscript{max} of the metastatic lymph nodes was 2.5±0.6 for stage 1, 3.2±1.8 for stage 2, 4.7±2.0 for stage 3 and 6.7±3.9 for stage 4.

K-ras mutation was assessed in 22 patients and 11 of patients had K-ras mutation (50%). There was no association between K-ras mutation and the primary tumor SUV\textsubscript{max} or metastatic tumor SUV\textsubscript{max} (p=0.358 and p=0.643, respectively). There was no correlation between tumor localization, angiolymphatic invasion, perineural invasion of the primary tumor and DFS or OS (p>0.05). A higher maximum diameter of the primary tumor and the number of metastatic lymph node or positive venous invasion of tumor predicted worse DFS in patients (p=0.012, p=0.03, p=0.024, respectively).

| Table 1. Patient characteristics |
|----------------------------------|
| Characteristics                 | All patients n=115 (%) |
| Sex                              |                         |
| Female                          | 39 (33.9)               |
| Male                            | 76 (66.1)               |
| Age (years)                     | 58.7±11.4               |
| Histopathologic tumor type      |                         |
| Adenocarcinoma                  | 115 (100)               |
| TNM stage, AJCC*                |                         |
| 1                               | 11 (9.5)                |
| 2                               | 42 (36.5)               |
| 3                               | 39 (34.0)               |
| 4                               | 23 (20.0)               |
| pT stage, AJCC*                 |                         |
| 2                               | 22 (19.1)               |
| 3                               | 76 (66.1)               |
| 4                               | 17 (14.8)               |
| pN stage, AJCC*                 |                         |
| 0                               | 66 (57.4)               |
| 1                               | 37 (32.2)               |
| 2                               | 12 (10.4)               |

*AJCC: American Joint Committee on Cancer 8th edition, TNM: Tumor-node-metastasis
N-stage was determined to be significant on DFS and OS (p=0.001, p=0.021, respectively). According to TNM stage, 23 patients had metastases (17 liver, 10 thorax, 11 non-regional lymph nodes, 3 peritoneum and 1 bone metastases) at diagnosis. Metastatic disease had predictive value on both DFS and OS (p<0.001).

**Discussion**

Rectal cancer is a common malignancy and a common cause of mortality; thus, accurate staging of rectal cancer is extremely important in determining the prognosis of the disease and the treatment protocol (9). The overall predicted 5-year survival rate after diagnosis is less than 60% but it is significantly dependent on disease stage (10). One of the most used techniques to detect prognosis in clinical practice is \(^{18}\)F-FDG PET/CT (11); providing a semi-quantitative measure of the metabolism of the tumoral lesion that is a comparative rate of tumoral proliferation (12). In patients with lung cancer and esophageal cancer, the SUV\(_{\text{max}}\) is a predictive value for survival. Primary tumor \(^{18}\)F-FDG uptake in non-small cell lung cancer was demonstrated to be the most potent prognostic factor in the curative treatment patient group (13). As the same, the initial \(^{18}\)F-FDG uptake was predictive of survival in esophageal cancer (14). In the light of this data, primary tumor SUV\(_{\text{max}}\) of rectal cancer for predicting survival has been investigated in previous studies and SUV\(_{\text{max}}\) has been asserted as a prognostic factor (15). However, in a study to assess the prognostic value of preoperative

![Figure 1. Kaplan-Meier survival analysis of all patients](image1)

| Table 2. Correlation between histopathological features, SUV\(_{\text{max}}\) values and survival rates |
|------------------------------------------------|
| **Values** | **p value for DFS and OS, respectively** |
| Primary tumor SUV\(_{\text{max}}\) (mean ± SD) | 21.0±9.1 (7.6-55) | p=0.760, p=0.525 |
| Lymph node SUV\(_{\text{max}}\) (mean ± SD) | 4.6±2.8 (1.7-14.9) | p=0.049, p=0.045 |
| Maximum diameter of the primary tumor (mm) | 36.9±16 (15-82) | p=0.012, p=0.092 |
| Number of metastatic lymph nodes | 1.21±2.5 (0-16) | p=0.030, p=0.605 |
| Positive perineural invasion (%) | 50 | p=0.765 |
| Positive angiolymphatic invasion (%) | 78 | p=0.292 |
| Positive venous invasion (%) | 33 | p=0.024 |
| Positive K-ras mutation | 50 | p=1 |

SUV\(_{\text{max}}\): Maximum standard uptake value, SD: Standard deviation, DFS: Disease-free survival, OS: Overall survival

![Figure 2. ROC analysis of lymph node SUV\(_{\text{max}}\) (blue) with DFS](image2)
18F-FDG PET/CT, Lee et al. (16) detected that SUV_{max} was not a significant predictor of recurrence or DFS. In a rectal cancer patient group that received neoadjuvant radiation therapy, Ooku et al. (17) found that pretreatment 18F-FDG PET/CT SUV_{mean} was unrelated to disease recurrence or response to therapy. In the study by Bang et al. (18), SUV_{mean}, SUV_{peak} and SUV_{max} were not associated with recurrence or neoadjuvant radiation and chemotherapy in locally advanced rectal cancer. In a study of 100 patients by Deantonio et al. (7); higher level of metabolic parameters was significantly associated with higher clinical tumor stage that was considered as more aggressive, but none of the analyzed metabolic parameters had any significant correlation with DFS or OS. In a study conducted by Ogawa et al. (19); it was shown that OS did not differ significantly between low and high SUV_{max} and SUV_{mean} groups. On the other hand, Dehdashti et al. (20) found that high 18F-FDG uptake (≥14.3) on initial PET/CT correlated with better DFS and better neoadjuvant therapy response, and so on better outcomes contrary to prior studies. Regarding the patient results in our study, increased FDG uptake of the primary tumor was shown in all patients. As the preoperative results in our study, increased FDG uptake of the primary tumor was shown in all patients. As the preoperative SUV_{max} of the lymph nodes was predictive of low survival. The other significant finding in our study was that the high SUV_{max} of the lymph nodes was predictive of low survival. In this respect, prior literature studies have put forward several and conflicting data about the relationship between survival and PET parameters such as primary tumor SUV_{max}, MTV and post-treatment metabolic changes (7,18,26,27). Chen et al. (25) showed that preoperative SUV lymph node measured on 18F-FDG PET/CT could predict the recurrence in patients with colorectal carcinoma. In our study, we assessed only the patients with rectal carcinoma. Furthermore, in addition to DFS, OS was evaluated, as well. The higher level of lymph node SUV_{max} in preoperative 18F-FDG PET/CT was significantly related to the more advanced clinical stage of the disease that was associated with more aggressive disease and poor survival outcomes. Morphological criteria such as lymph node size and number, which were higher in advanced stages, were considerable in this issue due to partial volume effect in small lymph nodes <10 mm in size leading to underestimation of true SUV (28).

Bang et al. (18) showed that lymphatic and venous involvements were not significantly associated with 3-year DFS, whereas in our study positive venous invasion had a prognostic impact (worse DFS). Chen et al. (29) reported that the mutated K-ras tumors were associated with higher 18F-FDG accumulation and higher SUV_{max} was a predictor of K-ras mutations. We should note that in our study, due to the retrospective nature, only 20 patients’ K-ras results were interpreted and there was no correlation between K-ras results and 18F-FDG PET/CT metabolic parameters. Furthermore, it has been reported that there is a heterogeneity of K-ras status among the primary rectal tumor (30). As a result, the correlation analysis might be biased because of the small patient group and dissected specimens for mutational testing could not reflect the real status of the total tumor, and 18F-FDG PET/CT displayed the entire status of tumor (31).

In this retrospective study, we found that primary tumor SUV_{max} in preoperative staging 18F-FDG PET/CT scan had no effect on predicting survival. On the other hand, the SUV_{max} of lymph nodes in 18F-FDG PET/CT was predictive regarding survival. Our results showed that the staging system which was still used in clinical practice was effective on predicting survival of patients with rectal cancer.

**Study Limitations**

There were some limitations in this study. First of all, it was a retrospective, single-institution study; thus, the findings of 18F-FDG-PET/CT as a prognostic factor in preoperative
rectal cancer required strengthening in a prospective, multicenter study with a larger patient number. Another weakness was the small sample size of patients and the heterogeneity of the clinical stages of the disease in the patient group that might have biased the outcome of this study. Additionally, we chose the SUV\textsubscript{max}, cut-off values from the ROC curves for the balance of sensitivity and specificity. However, these choices could be improved with a larger and homogeneous patient group.

**Conclusion**

The results showed that primary tumor SUV\textsubscript{max} obtained in initial \textsuperscript{18}F-FDG PET/CT was not predictive of survival in patients with rectal cancer. On the other hand, the lymph node SUV\textsubscript{max} had negative effect on survival. For this reason, we suggest the use of high lymph node SUV\textsubscript{max} as a new parameter for clinical practice, which has a negative impact on survival.

**Ethics**

**Ethics Committee Approval:** The study was approved by the İstanbul University Istanbul Medical Faculty of Local Ethics Committee (2015/1867).

**Informed Consent:** The consent form was filled out by all participants.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

Surgical and Medical Practices: G.A., G.Y., Concept: G.A., Y.Ş., Design: G.A., Y.Ş., E.K.S., Data Collection or Processing: G.A., G.Y., Analysis or Interpretation: G.A., Y.Ş., T.F.Ç., Literature Search: G.A., Y.Ş., Writing: G.A.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**

1. Nishihara R, Ogino S, Chan AT. Colorectal-cancer incidence and mortality after screening. N Engl J Med 2013;369:2355.
2. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-387.
3. Hong TS, Ryan DP. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: The New Standard of Care? JAMA Oncol 2018;4:e180070.
4. Ozis SE, Soydall C, Akyl C, Can N, Kucuk ON, Yaga C, Erkek AB, Kuzu MA. The role of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer. World J Surg Oncol 2014;12:26.
5. Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, Huang P, Tan S, Hu P, Wang J, Huang M. Elevated tumor-to-liver uptake ratio (TLR) from \textsuperscript{18}F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging 2017;44:1958-1968.
6. Nakajo M, Kajya Y, Tani A, Jingui M, Nakajo M, Kitazono M, Yoshiura T. A pilot study for texture analysis of \textsuperscript{18}F-FDG and \textsuperscript{18}F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery. Eur J Nucl Med Mol Imaging 2017;44:2158-2168.
7. Deantonio L, Caroli A, Pata E, Ferrante D, Apicella F, Turri L, Zacchetti G, Brambilla M, Krenchl M. Does baseline \textsuperscript{18}F FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer? Radiat Oncol 2018;13:211.
8. Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol 2018;25:1454-1455.
9. Engelen SM, Beets-Tan RG, Lahaye M, Kessels AG, Beets GL. Location of involved mesorectal and extramesorectal lymph nodes in patients with primary rectal cancer: preoperative assessment with MR imaging. Eur J Surg Oncol 2008;34:776-781.
10. National Institute for Health and Clinical Excellence. Improving outcomes in colorectal cancer. Manual update. London: National Institute for Health and Clinical Excellence; 2004.
11. Tagliaflue L. The emerging role of FDG PET/CT in rectal cancer management: is it time to use the technique for early prognostication? Eur J Nucl Med Mol Imaging 2018;45:2013-2014.
12. Kijima S, Sasaki T, Nagata K, Utano K, Lefor AT, Sugimoto H. Preoperative evaluation of colorectal cancer using CT colonography, MRI, and PET/CT. World J Gastroenterol 2014;20:16964-16975.
13. Sasaki R, Komaki R, Maccapani H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. \textsuperscript{18}F fluoro-deoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-1143.
14. Pan L, Hu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009;21:1008-1015.
15. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. \textsuperscript{18}F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771-775.
16. Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST, Yoo I, Kim SH. Prognostic value of \textsuperscript{18}F-fluorodeoxyglucose positron-emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol 2012;18:5072-5077.
17. Oktu S, Nakagawa K, Nomose T, Nakamura Y, Abe A, Watanabe T, Ohtomo K. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002;16:409-416.
18. Bang JH, Ha S, Kang SB, Lee KW, Lee HS, Oh HK, Lee HY, Kim SE. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment \textsuperscript{18}F FDG PET/CT scans in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging 2016;43:422-431.
19. Ogawa S, Itabashi M, Kondo C, Nomose M, Sakai S, Kameoka S. Prognostic value of total lesion glycolysis measured by \textsuperscript{18}F-FDG-PET/CT in patients with colorectal cancer. Anticancer Res. 2015;35:3959-3960.
20. Dehdashti F, Grigby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA. Positron emission tomography with \textsuperscript{18}F-f-2-deoxy-2-fluorouridine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol 2013;15:106-113.
21. Cerny M, Dunet V, Prior L, Hahnloser D, Wagner AD, Meuli RA, Schmidt S. Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With \textsuperscript{18}F-FDG-PET/CT. Clin Nucl Med 2016;41:289-295.
22. Zhou L, Wang ZZ, Wang JT, Wu YJ, Chen H, Wang WB, Cao F, Cheng
23. Glynn-Jones R, Wyrwicz L, Tret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):22-40.

24. Bae SU, Won KS, Song BI, Jeong WK, Baek SK, Kim HW. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer. Cancer Imaging 2018;18:32.

25. Chen R, Wang Y, Zhou X, Huang G, Liu J. Preoperative PET/CT 18F-FDG Standardized Uptake by Lymph Nodes as a Significant Prognostic Factor in Patients with Colorectal Cancer. Contrast Media Mol Imaging 2018;2018:5802109.

26. Leccisotti L, Gambacorta MA, de Waure C, Stefanelli A, Barbaro B, Vecchio FM, Coco C, Persiani R, Crucitti A, Tortorelli AP, Giordano A, Valentini V. The predictive value of 18F- FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2015;42:657-666.

27. Alongi F, Fersino S, Mazzola R, Fiorentino A, Giaj-Levra N, Ricchetti F, Ruggieri R, Di Paola G, Cirillo M, Gori S, Salgarello M, Zamboni G, Ruffo G. Radiation dose intensification in preoperative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl Oncol 2017;19:189-196.

28. Rahmim A, Qi J, Sossi V. Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys 2013;40:064301.

29. Chen SW, Chiang HC, Chen WT, Hsieh TC, Yen KY, Chiang SE, Kao CH. Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med 2014;39:685-689.

30. Baldus SE, Schaefer KI, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.

31. Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, Hasegawa S, Togashi K, Sakai Y. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res 2012;18:1696-1703.